$MNOV still climbing. Pr Nasdaq $7.70 Called 9/
Post# of 63700
Posted On: 03/30/2016 5:03:25 PM
$MNOV still climbing. Pr
Nasdaq $7.70
Called 9/2/14 $2.35
MediciNova Receives Notice of Allowance
for New Patent Covering MN-001 in China
GlobeNewswire (Sun, Mar 27)
Website
Shares Outstanding: 30.00M
Float: 26.74M
% Held by Insiders: 22.50%
% Held by Institutions: 8.50%
Shares Short (as of Mar 15, 2016): 1.52M
Short Ratio (as of Mar 15, 2016): 4.31
Short % of Float (as of Mar 15, 2016): 6.98%
Shares Short (prior month): 1.16M
Headlines
Company Profile - MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs for the United States market. Its product candidates include MN-166 (Ibudilast), an anti-inflammatory and neuroprotective agent, which has completed Phase II clinical trials for the treatment of neurological disorders; MN-221 (Bedoradrine), a ß2-adrenergic receptor agonist that has completed Phase IIb clinical trails for the treatment of acute exacerbations of asthma; MN-001 (Tipelukast), an orally bioavailable small molecule compound, which has completed a pre-clinical study for the treatment of nonalcoholic steatohepatitis; and MN-029 (Denibulin), a novel tubulin binding agent under development for the treatment of solid tumors. MediciNova, Inc. was founded in 2000 and is based in La Jolla, California.
Nasdaq $7.70
Called 9/2/14 $2.35
MediciNova Receives Notice of Allowance
for New Patent Covering MN-001 in China
GlobeNewswire (Sun, Mar 27)
Website
Shares Outstanding: 30.00M
Float: 26.74M
% Held by Insiders: 22.50%
% Held by Institutions: 8.50%
Shares Short (as of Mar 15, 2016): 1.52M
Short Ratio (as of Mar 15, 2016): 4.31
Short % of Float (as of Mar 15, 2016): 6.98%
Shares Short (prior month): 1.16M
Headlines
Company Profile - MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs for the United States market. Its product candidates include MN-166 (Ibudilast), an anti-inflammatory and neuroprotective agent, which has completed Phase II clinical trials for the treatment of neurological disorders; MN-221 (Bedoradrine), a ß2-adrenergic receptor agonist that has completed Phase IIb clinical trails for the treatment of acute exacerbations of asthma; MN-001 (Tipelukast), an orally bioavailable small molecule compound, which has completed a pre-clinical study for the treatment of nonalcoholic steatohepatitis; and MN-029 (Denibulin), a novel tubulin binding agent under development for the treatment of solid tumors. MediciNova, Inc. was founded in 2000 and is based in La Jolla, California.
(0)
(0)Scroll down for more posts ▼